Theravance cuts 17% of staff, JAK inhibitor program

Theravance Biopharma is cutting 17% of its workforce and a mid-stage inhaled JAK inhibitor program, it announced Monday afternoon.

Theravance will be discontinuing work on its inhaled JAK inhibitor nezulcitinib, which failed a trial in Covid-19 patients in 2021. As a result, Theravance said, it will…